[go: up one dir, main page]

WO2012008711A3 - Erlotinib dichloroacetate and anti-cancer agent comprising the same - Google Patents

Erlotinib dichloroacetate and anti-cancer agent comprising the same Download PDF

Info

Publication number
WO2012008711A3
WO2012008711A3 PCT/KR2011/004985 KR2011004985W WO2012008711A3 WO 2012008711 A3 WO2012008711 A3 WO 2012008711A3 KR 2011004985 W KR2011004985 W KR 2011004985W WO 2012008711 A3 WO2012008711 A3 WO 2012008711A3
Authority
WO
WIPO (PCT)
Prior art keywords
erlotinib
dichloroacetate
same
cancer agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/004985
Other languages
French (fr)
Other versions
WO2012008711A2 (en
Inventor
Kyoung Soo Kim
Young Jun Park
Hyun-Nam Song
Dong Youn Kim
Joon Woo Kim
Kyoung-Suk Cho
Keewon Yu
Hyuk Jin Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltrion Pharm Inc
Celltrion Chemical Research Institute
Original Assignee
Celltrion Pharm Inc
Celltrion Chemical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Pharm Inc, Celltrion Chemical Research Institute filed Critical Celltrion Pharm Inc
Publication of WO2012008711A2 publication Critical patent/WO2012008711A2/en
Publication of WO2012008711A3 publication Critical patent/WO2012008711A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to erlotinib dichloroacetate and an anti-cancer agent comprising the same. The erlotinib dichloroacetate of the present invention can inhibit epidermal growth factor receptor as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid.
PCT/KR2011/004985 2010-07-15 2011-07-07 Erlotinib dichloroacetate and anti-cancer agent comprising the same Ceased WO2012008711A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0068603 2010-07-15
KR1020100068603A KR101208956B1 (en) 2010-07-15 2010-07-15 Erlotinib dichloroacetate and anti-cancer agent comprising the same

Publications (2)

Publication Number Publication Date
WO2012008711A2 WO2012008711A2 (en) 2012-01-19
WO2012008711A3 true WO2012008711A3 (en) 2012-05-24

Family

ID=45469896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004985 Ceased WO2012008711A2 (en) 2010-07-15 2011-07-07 Erlotinib dichloroacetate and anti-cancer agent comprising the same

Country Status (2)

Country Link
KR (1) KR101208956B1 (en)
WO (1) WO2012008711A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (en) * 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN102584719A (en) * 2012-02-02 2012-07-18 瑞阳制药有限公司 Preparing technology of erlotinib hydrochloride
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
KR101998246B1 (en) * 2018-08-22 2019-07-10 주식회사 메타파인즈 A pharmaceutical composition for treating cancer comprising an ionic compound having metal ions binding thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900221B1 (en) * 1999-11-11 2005-05-31 Osi Pharmaceuticals, Inc. Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
US20080058355A1 (en) * 2006-07-28 2008-03-06 Westheim Raymond J H Crystalline erlotinib
US20100130741A1 (en) * 2007-07-11 2010-05-27 Hetero Drugs Limited Process for erlotinib hydrochloride

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900221B1 (en) * 1999-11-11 2005-05-31 Osi Pharmaceuticals, Inc. Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
US20080058355A1 (en) * 2006-07-28 2008-03-06 Westheim Raymond J H Crystalline erlotinib
US20100130741A1 (en) * 2007-07-11 2010-05-27 Hetero Drugs Limited Process for erlotinib hydrochloride

Also Published As

Publication number Publication date
WO2012008711A2 (en) 2012-01-19
KR20120007848A (en) 2012-01-25
KR101208956B1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
IN2012DN02081A (en)
UA111386C2 (en) PYRIDOPIRASES THAT HAVE ANTI-CANCER ACTIVITY THROUGH FGFR-KINAS INHIBITION
MY203474A (en) Substituted tricyclic compounds as fgfr inhibitors
MX369472B (en) Inhibitors of the fibroblast growth factor receptor.
PH12013501600A1 (en) Novel heterocyclic derivatives
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2016008448A (en) Var2csa-drug conjugates.
CA2873723A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
NZ709153A (en) Pyrimidinone derivatives having human neutrophil elastase inhibitory activity
WO2011123427A9 (en) Treatment of cancer by inhibiting activity or expression of late sv-40 factor
EP2343051A3 (en) Anti-cancer formulation
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2013112699A3 (en) Proteasome activity enhancing compounds
PL2729008T3 (en) Systems, methods and formulations for the treatment of cancer
WO2011081408A3 (en) Imatinib dichloroacetate and anti-cancer agent comprising the same
MX357166B (en) Antibodies to notum pectinacetylesterase.
WO2012162513A3 (en) Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
WO2011130697A3 (en) Tissue targeting
WO2012008711A3 (en) Erlotinib dichloroacetate and anti-cancer agent comprising the same
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
UA115523C2 (en) Solid state forms of macrocyclic kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11806996

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11806996

Country of ref document: EP

Kind code of ref document: A2